US 12,134,594 B2
Composition and application thereof as antitumor drug
Xiaojiang Tang, Guangzhou (CN); Xuefeng Ren, Guangzhou (CN); Yichen Ge, Guangzhou (CN); Zhiyong Zhong, Guangzhou (CN); and Nina Zheng, Flushing, NY (US)
Assigned to Guangdong Jianersheng Pharmaceutical Technology Co., Ltd., Zhuhai (CN)
Filed by Guangdong Jianersheng Pharmaceutical Technology Co., Ltd., Guangdong (CN)
Filed on Mar. 23, 2021, as Appl. No. 17/209,337.
Application 17/209,337 is a continuation in part of application No. PCT/CN2019/087023, filed on May 15, 2019.
Claims priority of application No. 201811185272.8 (CN), filed on Oct. 11, 2018.
Prior Publication US 2021/0276948 A1, Sep. 9, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 33/243 (2019.01); C07C 333/04 (2006.01)
CPC C07C 333/04 (2013.01) [A61K 33/243 (2019.01); A61P 35/00 (2018.01)] 7 Claims
 
1. A method of treating solid tumors in a subject suffering from cancer, including:
administering a drug to the subject, wherein the drug comprises, in parts by mole, 1-5 parts of a platinum-based antitumor compound and 1-50 parts of sodium (S)-2-(dithiocarboxylate ((2S,3R,4R),5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4-(methylthio)butyrate (GMDTC).